Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K. Cognetti F, et al. Among authors: scambia g. Gynecol Oncol. 2013 Jul;130(1):31-7. doi: 10.1016/j.ygyno.2012.12.004. Epub 2012 Dec 9. Gynecol Oncol. 2013. PMID: 23234805 Clinical Trial.
CA 15-3 serum levels in ovarian cancer.
Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Di Roberto P, Mancuso S. Scambia G, et al. Oncology. 1988;45(3):263-7. doi: 10.1159/000226575. Oncology. 1988. PMID: 3163419
CA 15-3 as a tumor marker in gynecological malignancies.
Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Mancuso S. Scambia G, et al. Gynecol Oncol. 1988 Jun;30(2):265-73. doi: 10.1016/0090-8258(88)90032-7. Gynecol Oncol. 1988. PMID: 3163666
2,074 results